Navigation Links
Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing

arrow aplasia is defined by two parameters: the extent and the duration of cytopenias, particularly neutropenia. There is a clear relation between these two parameters and the incidence of infection, which is high after one week of polynuclear levels below 500 cells/mm3. The same applies to thrombopenia and the risk of bleeding, which increases with platelet counts below 30,000 platelets/mm3, and becomes more serious as counts drop further. A distinction is made between short-term aplasia (<1 week) and long term aplasia (>1 week). Anti-infection strategies take into account the expected duration of the aplasia, its conditions of onset (e.g. during leukemia induction therapy, which may be associated with a pre-existing infection), and fever monitoring, associated with pathogen identification in only 25-30% of these cases, leading to emergency requirements in some instances. Based on solid clinical analysis and a few simple laboratory tools, such as CBC and CRP measurement, concise decisions on patient management can be made.

CRP testing is used in monitoring infection profiles by noting increasing levels, which correlate with temperature fluctuations during fever. This allows a dynamic analysis of the infection progression and can lead to more accurate and prompt administration of antibiotic treatment, or withdrawal of antibiotic therapy if required. Conversely an observed drop in CRP levels and a rise in white blood cells (WBC) can allow an earlier patient discharge. The combination of CRP and CBC analyses can therefore improve the follow-up of aplasia patients who may have other hematological diseases. Thus, relocating these tests closer to the patients bedside is obvious as it provides reliability, simplicity and a rapid turnaround of results. Used as part of a cost-control plan, near-patient CRP and CBC testing can reduce the costs associated with inappropriate antibiotic treatment and prolonged hospital stays. Moreov
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Rapid Whole Blood Testing for Infectious Mononucleosis Antibodies
2. PSA TestingHow Much is Too Much?
3. Hemoglobin Testing at the Point of Care
4. Testing for Human Papillomavirus
5. Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing
6. Rapid HIV Testing Increases Possibility of Treatment
Post Your Comments:
(Date:5/8/2008)...search Alliance, an,organization comprised of 12 o...illion Americans to exercise their power over canc...Mother,s Day through Father,s Day., The campaign,...y goals:,to activate Americans everywhere to take ...o exercise their collective power over cancer, and...
(Date:5/8/2008)...herapeutic Proteins at Tumor,Site, ARLINGTON HE...g gene,therapy, plastic surgeons have delivered ca...n cancerous tumors on rats with a 79 percent reduc...May issue of Plastic and,Reconstructive Surgery(R)...iety of Plastic Surgeons (ASPS). This new delivery...
(Date:5/8/2008)...ll/ -- AstraZeneca (NYSE:,AZN) today announced the...,(sNDA) to the U.S. Food and Drug Administration (...ended-Release Tablets to seek approval for the,tre...uding maintenance of,antianxiety effect. It is the...al antipsychotic medicine in GAD. The submission i...
(Date:5/7/2008)...Arena Pharmaceuticals, Inc.,(Nasdaq: ARNA ) annou...itiated a Phase 1 clinical trial of a drug candida...develop compounds to treat psychiatric disorders.,...ed for the treatment of a,common psychiatric disor... partner, Taisho,effectively continue its efforts...
Breaking Medicine Technology:World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 2World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 3World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 4World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 5Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals 2Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals 3AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 2AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 3AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 4AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 5AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 6AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 7AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 8Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd. 2Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd. 3Memory tasks require more coordinated brain blood flow for people with high blood pressure 2262 1Memory tasks require more coordinated brain blood flow for people with high blood pressure 2262 2Memory tasks require more coordinated brain blood flow for people with high blood pressure 2262 3HortTalks a valuable scientific resource 598 1HortTalks a valuable scientific resource 598 2Wyeth Announces Election of Bernard Poussot as CEO of Company Effective January 1 2008 2259 1Wyeth Announces Election of Bernard Poussot as CEO of Company Effective January 1 2008 2259 2Insulet Awarded National Accreditation for Excellence by Community Health Accreditation Program 2255 1Insulet Awarded National Accreditation for Excellence by Community Health Accreditation Program 2255 2
...e nanomedicine company,focused on the development ...rgeted therapies today presented a poster,abstract... (ASCO),Annual meeting. The poster, entitled "Prel...-6901," announced the preliminary data,of a Nation...es,sponsored Phase 1 trial of CYT-6091 (Aurimune),...
...ine provide support for,epigenetic and combination...use of Thalidomide to treat multiple myeloma, BOUL... Pharmion,Corporation reported today that data fro...y,s marketed and pipeline products will be,present...l,Oncology,s (ASCO) 43rd Annual Meeting in Chicago...
Other Medicine Technology:CytImmune Presents Positive CYT-6019 Data During the American,Society of Clinical Oncology Annual Meeting in Chicago 2CytImmune Presents Positive CYT-6019 Data During the American,Society of Clinical Oncology Annual Meeting in Chicago 3Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 2Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 3Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 4Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 5Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 6Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 7
(Date:5/12/2008)...irstCall/ -- NBTY, Inc. (NYSE:,NTY) (http://www.N...ter of,nutritional supplements, today announced th...s for the month of April 2008 by segment:, , ... (Preliminary and Unaudited) ... ($ In Millions), ...
(Date:5/12/2008)...May 12, 08:30 a.m. EDT at ...ay 12 /PRNewswire-FirstCall/ -- Isis,Pharmaceutica...ncial results,for the quarter ended March 31, 2008...a net operating loss (NOL) of $5.1 million, exclud... compared to a pro forma NOL,of $18.5 million in t...
(Date:5/12/2008)...FirstCall/ -- Cepheid (Nasdaq:,CPHD) today announc...Premier, Inc., one of the largest U.S. Group Purch...rticipating hospitals and 42,000 other,healthcare ... has also,signed a preferred vendor agreement with..., a collaboration of 53 acute care hospitals that ...
(Date:5/12/2008)...all/ - Innolife Pharma, Inc.,(Other OTC:INNP.PK - ...ht,months regarding the formation of a joint ventu...negotiations where final written terms have been,s... Company,s very first,product acquisition. It shou... over this extended period due to the successful, ...
Breaking Medicine News(10 mins):Health News:NBTY Announces Preliminary Unaudited Net Sales Results for April 2008 2Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 2Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 3Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 4Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 5Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 6Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 7Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 8Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 9Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 10Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 11Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 12Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 13Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 14Health News:Cepheid Signs Group Purchasing Contract With Premier Healthcare Alliance, One of the Largest U.S. Group Purchasing Organizations 2Health News:Cepheid Signs Group Purchasing Contract With Premier Healthcare Alliance, One of the Largest U.S. Group Purchasing Organizations 3Health News:Cepheid Signs Group Purchasing Contract With Premier Healthcare Alliance, One of the Largest U.S. Group Purchasing Organizations 4Health News:Innolife Pharma Provides Initial Update on Negotiations for Significant Product Joint Venture 2
...cular diseases for better in as early as eight wee...ference on Arteriosclerosis, Thrombosis and Vascul...se regimen with Mediterranean type diet may bring ...tion and effectiveness for people who have a high ...
...vily to high blood pressure and cardiovascular dis...can happen through transcendental meditation progr...se diseases. For population over 55 years of age, ...ife, interventions in the form of meditation may h...
...on of Clopidogrel and aspirin is more effective th... 107 participants across four countries of the Eur...aspirin. Each of the participants of the study had...attack (TIA). All the patients have at least 50% n...
...a common procedure. A new research says that influ...gnant mothers as a precautionary measure. Influenz...e containing killed virus that is injected into th... older than 6 months, including people with chroni...
Other Medicine News:
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
CUSA DISSECTRON PORTABLE UNIT is an ultrasonic surgical aspirator for the fragmentation and emulsification of tissue available only outside the United States.
Medicine Products: